Зарегистрироваться

Имя пользователя

Имя

Фамилия

E-mail

Пароль

Подтвердить Пароль

Срок проверки reCAPTCHA истек. Перезагрузите страницу.

Only fill in if you are not human

Войти

Найти:

Свежие записи

Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
Главные ошибки при формировании базы данных в MS Excel
Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
Julia:ReplicateBE – release 0.2.0

Галерея

Human medicines European public assessment report (EPAR): Dupixent, dupilumab, Date of authorisation: 26/09/2017, Revision: 38, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2024-12-02
Human medicines European public assessment report (EPAR): Fabhalta, Iptacopan, Date of authorisation: 17/05/2024, Revision: 2, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2024-12-02
GDUFA Paid Facilities List
Source: FDA - What's New: Drugs RSS Feed Published on 2024-11-29 By FDA
Human medicines European public assessment report (EPAR): Beovu, brolucizumab, Date of authorisation: 13/02/2020, Revision: 14, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2024-11-29
Human medicines European public assessment report (EPAR): Lutetium (177Lu) chloride Billev (previously Illuzyce), lutetium (177Lu) chloride, Date of authorisation: 15/09/2022, Revision: 3, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2024-11-29
Human medicines European public assessment report (EPAR): Eylea, aflibercept, Date of authorisation: 21/11/2012, Revision: 35, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2024-11-29
Human medicines European public assessment report (EPAR): Onivyde pegylated liposomal (previously known as Onivyde), irinotecan hydrochloride trihydrate, Date of authorisation: 14/10/2016, Revision: 14, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2024-11-29
Human medicines European public assessment report (EPAR): Obizur, susoctocog alfa, Date of authorisation: 11/11/2015, Revision: 12, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2024-11-29
Human medicines European public assessment report (EPAR): Akantior, polihexanide, Date of authorisation: 22/08/2024, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2024-11-29
Human medicines European public assessment report (EPAR): Duloxetine Zentiva, duloxetine, Date of authorisation: 20/08/2015, Revision: 13, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2024-11-29
Human medicines European public assessment report (EPAR): Signifor, pasireotide, Date of authorisation: 24/04/2012, Revision: 15, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2024-11-28
UPDATED MEETING TIME AND PUBLIC PARTICIPATION INFORMATION: December 4, 2024: Meeting of the Pharmacy Compounding Advisory Committee - 12/04/2024
Source: FDA - What's New: Drugs RSS Feed Published on 2024-11-28 By FDA
CDER Small Business and Industry Assistance (SBIA) Learn
Source: FDA - What's New: Drugs RSS Feed Published on 2024-11-27 By FDA
Pharmacy Compounding Advisory Committee Roster
Source: FDA - What's New: Drugs RSS Feed Published on 2024-11-27 By FDA
LipoFit Turbo may be harmful due to hidden drug ingredients
Source: FDA - What's New: Drugs RSS Feed Published on 2024-11-27 By FDA

Предыдущие записи

Тема: Scaffold от Danny Cooper.